Indium pentetreotide
As of the edition of 20 October 2026, Indium pentetreotide is a protein: marketed, first approved in 1994 (US); acts on SSTR1, SSTR2 and SSTR3 and 2 more; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1994
- Kind
- Protein
- Brand name
- Octreoscan
- First approved
- 2 June 1994 (US)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Curium
- Registered trials
- 3, 1 stopped early
- Disease areas
- Cancer; Blood and lymph; Digestive system; Hormones; Immune system
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Companies that need a new molecule because of this drug
5 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product5 company-target rows are on route B because of Indium pentetreotide.
See the 5 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 1 | 0 | 0 |
| Phase 3 | 1 | 1 | 0 | 0 |
| Phase 4 | 1 | 0 | 0 | 1 |
| All trials | 3 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Byk-Mallinckrodt CIL | Originator and Lead sponsor of trials | 1994 to now |
| Curium | Acquired holder | 2019 to now |